^
Association details:
| Biomarker: | PSMA1 overexpression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).
Published date:
05/25/2023
Excerpt:
48 pts with mCRPC and high PSMA expression...Across cohorts 1-9, the PSA50-RR was 62% (18/29) and PSA90-RR was 48% (14/29). Five of the 7 pts (71%) with RECIST measurable disease had a partial response….The combination of 177Lu-PSMA-617 and olaparib is well tolerated and has promising activity.
DOI:
10.1200/JCO.2023.41.16_suppl.5005
Trial ID:
